Lataa...
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
BACKGROUND: We report the re-biopsied diagnosis of a patient with anaplastic lymphoma receptor tyrosine kinase (ALK)-positive lung adenocarcinoma successfully treated with ceritinib 450 mg/day taken with food following disease progression and gastrointestinal intolerance to crizotinib. CASE PRESENTA...
Tallennettuna:
| Julkaisussa: | BMC Cancer |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4969677/ https://ncbi.nlm.nih.gov/pubmed/27480287 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2636-z |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|